Hallucinogens

Richard Laing is an Analytical Specialist with Health Canada's Drug Analysis Service Laboratory in Burnaby, BC and has an MSc specializing in the Mass Spectrometry and Nuclear Magnetic Resonance spectroscopy of natural products. He has spent the last twelve years working in clandestine laboratory investigations and is recognized as a leading Canadian expert in this field. His experience and seizure of clandestine laboratories transcends many drug types including Methamphetamine, Ecstasy, LSD, and Psilocybin production. Richard is a member on the International forensic drug standard setting committee SWGDrug. Richard also is a faculty member at the British Columbia Institute of Technology in the Faculty of Forensic Science. Jay Siegel, PhD is retired Director of the Forensic and Investigative Sciences Program and Chair of the Department of Chemistry and Chemical Biology at Indiana University Purdue University Indianapolis. He was Director of the Forensic Science Program at Michigan State University for 25 years from 1980-2004 until his retirement as Professor Emeritus. Dr. Siegel is a Distinguished Member of the American Academy of Forensic Sciences and was named as Distinguished Alumni Scholar by his alma mater, George Washington University in 2011. He is co-editor of Forensic Science Policy and Management: An International Journal. He was a member of the National Academy of Sciences Forensic Science Committee from 2006-09.

PREFACE vii
ABOUT THE AUTHORS ix
CHAPTER 1 HISTORY OF THE PSYCHEDELIC EXPERIENCE
1.0 ORIGIN
1.1 IDENTIFYING NATURAL SOURCES OF DRUGS AND THEIR ACTIVE CONSTITUENTS
1.2 WHAT WE HAVE NOT INCLUDED HERE
1.3 PSYCHEDELIC PLANTS
1.4 "MAGIC" MUSHROOMS
1.5 PEYOTE
1.6 OTHERS
1.7 ANIMAL-DERIVED HALLUCINOGENS
1.8 SOCIAL AND LEGAL CONSIDERATIONS
1.8 REFERENCES 31
CHAPTER 2 OCCURRENCES AND FORMS OF THE HALLUCINOGENS
2.0 INTRODUCTION
1.8 PART I: LSD:
2.1 LSD AND RELATED ANALOGS
2.2 FORMS OF THE DRUG
1.8 PART II: INDOLALKYLAMINES
2.3 PSILOCYBIN, BUFONTENINE AND OTHER SUBSTITUTED TRYPTAMINES
2.4 FORMS OF THE DRUGS
1.8 PART III: HALLUCINOGENIC PHENETHYLAMINES
2.5 MESCALINE/PEYOTE
2.6 MDA/MDMA
2.7 NEXUS (2-CB), STP, DOB, TMA
1.8 PART IV: PCP, PCP ANALOGS, AND KETAMINE
2.8 PCP AND KETAMINE
1.8 PART V: OTHERS
2.9 a-CARBOLINES
1.8 ACKNOWLEDGEMENTS
1.8 REFERENCES
CHAPTER 3 BASIC PHARMACOLOGY AND EFFECTS
3.0 INTRODUCTION: WHAT ARE THE HALLUCINOGENIC DRUGS?
3.1 THE PHENETHYLAMINES
3.2 THE TRYPTAMINES
3.3 SIGNIFICANT OTHERS
3.4 FEDERAL US DRUG LAW
1.8 REFERNCES
CHAPTER 4 METHODS OF ILLICIT MANUFACTURE
4.0 INTRODUCTION
4.1 ILLICIT MANUFACTURE
4.2 WORLDWIDE DISTRIBUTION
4.3 LAW ENFORCEMENT: AN INTERVIEW WITH AN LSD
CLANDESTINE CHEMIST
1.8 ACKNOWLEDGEMENTS
1.8 REFERNCES 182
CHAPTER 5 ANALYSIS OF THE HALLUCINOGENS
PART I: INFRARED SPECTROSCOPY:
5.0 THEORETICAL BASIS
5.1 INFRARED SPECTROMETER INSTRUMENTATION
5.2 INFRARED SPECTROSCOPY OF LSD
5.3 INFRARED SPECTROSCOPY OF PHENYLALKYLAMINES
5.4 INFRARED SPECTROSCOPY OF PHENCYCLIDINE AND ANALOGUES
5.5 INFRARED SPECTROSCOPY OF TRYPTAMINES
5.6 FURTHER READING
PART II: MASS SPECTROMETRY:
5.7 THEORETICAL BASIS
5.8 MASS SPECTROMETRY OF LSD
5.9 MASS SPECTROMETRY OF PHENYLALKYLAMINES
5.10 MASS SPECTROMETRY OF PHENCYCLIDINE AND ANALOGUES
5.11 MASS SPECTROMETRY OF TRYPTAMINES
5.12 FURTHER READING
PART III: NUCLEAR MAGNETIC RESONANCE SPECTROMETRY:
5.13 THEORETICAL BASIS
5.14 THE NMR EXPERIMENT
5.15 PHENCYCLIDINE AND RELATED SUBSTANCES
5.16 MDA AND ANALOGUES
5.17 ERGOT AND OTHER INDOLE ALKALOIDS
5.18 TRYPTAMINES
1.8 REFERENCES
INDEX